The Board of Directors of the Company at their meeting held on November 11, 2025 have inter alia approved; Unaudited Standalone Financial Results of the Company for the period ended on ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Mardia Samyoung Capillary Tubes reported its unaudited results for the quarter ended September 30, 2025, with revenue from operations jumping to ₹40.88 lakhs from just ₹0.58 lakhs in the same quarter last year. The company swung to a small profit of ₹1.72 lakhs (EPS ₹0.02) in Q2 FY26, compared to a loss of ₹22.88 lakhs a year ago. However, for the half-year (H1 FY26), the company remained deep in the red with a net loss of ₹142.56 lakhs versus a loss of ₹21.16 lakhs in H1 FY25, as expenses surged to ₹143.14 lakhs. The auditor S K Bhavsar & Co issued an unmodified/unqualified opinion but flagged an emphasis of matter noting that trade receivables, trade payables and loans/advances balances are still pending external confirmation and reconciliation. Net cash from operating activities was negative at ₹(3.48) lakhs in H1 FY26, though markedly better than ₹(253.46) lakhs in the prior-year period.
The sharp Q2 revenue rebound and swing to profit are encouraging signs, but the widening half-year loss, negative reserves of ₹(154.11) lakhs, and auditor's emphasis on unverified receivables, payables and loans raise governance concerns that could weigh on the stock.